Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Ychou

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 9, 2005
Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801)O Bouché, M Ychou, P Burtin, et al.
Journal of Visceral Surgery|August 31, 2019
Management of colorectal peritoneal metastases: Expert opinionK Abboud, T André, M Brunel, et al.
Clinics and Research in Hepatology and Gastroenterology|June 3, 2011
Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatmentE Samalin, P Afchain, S Thézenas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2002
A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinomaM Ducreux, P Rougier, J-P Pignon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2002
Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patientsJ-F Seitz, J Bennouna, B Paillot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer CentersY Bécouarn, M Ychou, M Ducreux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2009
A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)M Ychou, J-L Raoul, J-Y Douillard, et al.
British Journal of Cancer|April 16, 2009
TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapyA Oden-Gangloff, F Di Fiore, F Bibeau, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 29, 2017
Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs)U Ronellenfitsch, M Schwarzbach, R Hofheinz, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 30, 2017
Antibody targeting of claudin-1 as a potential colorectal cancer therapyS Cherradi, A Ayrolles-Torro, N Vezzo-Vié, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 9, 2005
Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801)O Bouché, M Ychou, P Burtin, et al.
Journal of Visceral Surgery|August 31, 2019
Management of colorectal peritoneal metastases: Expert opinionK Abboud, T André, M Brunel, et al.
Clinics and Research in Hepatology and Gastroenterology|June 3, 2011
Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatmentE Samalin, P Afchain, S Thézenas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2002
A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinomaM Ducreux, P Rougier, J-P Pignon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2002
Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patientsJ-F Seitz, J Bennouna, B Paillot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer CentersY Bécouarn, M Ychou, M Ducreux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2009
A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)M Ychou, J-L Raoul, J-Y Douillard, et al.
British Journal of Cancer|April 16, 2009
TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapyA Oden-Gangloff, F Di Fiore, F Bibeau, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 29, 2017
Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs)U Ronellenfitsch, M Schwarzbach, R Hofheinz, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 30, 2017
Antibody targeting of claudin-1 as a potential colorectal cancer therapyS Cherradi, A Ayrolles-Torro, N Vezzo-Vié, et al.
Pageof 11